BeOne Medicines (NASDAQ:ONC) Insider Sells $36,900.88 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Titus Ball sold 136 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $271.33, for a total value of $36,900.88. Following the completion of the transaction, the insider directly owned 36 shares of the company’s stock, valued at approximately $9,767.88. This trade represents a 79.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Up 1.6%

Shares of ONC stock opened at $264.48 on Friday. The stock has a market cap of $29.02 billion, a P/E ratio of 59.17 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22. The stock has a fifty day moving average price of $299.42 and a 200 day moving average price of $314.63. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Capital International Investors raised its holdings in shares of BeOne Medicines by 1.3% in the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after buying an additional 67,808 shares during the last quarter. Siren L.L.C. raised its holdings in shares of BeOne Medicines by 1.4% in the fourth quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock valued at $151,905,000 after buying an additional 7,010 shares during the last quarter. Morgan Stanley raised its holdings in shares of BeOne Medicines by 23.9% in the fourth quarter. Morgan Stanley now owns 437,661 shares of the company’s stock valued at $132,966,000 after buying an additional 84,367 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of BeOne Medicines by 7.0% in the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after buying an additional 26,441 shares during the last quarter. Finally, Candriam S.C.A. raised its holdings in shares of BeOne Medicines by 31.7% in the first quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after buying an additional 62,470 shares during the last quarter. 48.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on ONC shares. Wells Fargo & Company started coverage on BeOne Medicines in a report on Monday, May 4th. They set an “overweight” rating and a $400.00 price objective for the company. Leerink Partners lifted their price objective on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Morgan Stanley reissued an “overweight” rating and set a $395.00 price objective on shares of BeOne Medicines in a report on Thursday, May 7th. Barclays lifted their price objective on BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Finally, Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.